A Study of Surufatinib in the Treatment of Advanced Soft Tissue Sarcoma
Status:
Not yet recruiting
Trial end date:
2025-08-15
Target enrollment:
Participant gender:
Summary
This is a single-center, open, single-arm, phase II clinical study to investigate the
efficacy and safety of patients with soft tissue sarcoma who have failed
anthracycline-containing chemotherapy and whose antivascular agents have been effective and
failed.
Progression-free survival (PFS) was used as the primary outcome measure to preliminatively
estimate the efficacy and safety of 29 patients with soft tissue sarcoma who had failed
chemotherapy with anthracyclines and who had received effective and failed antivascular
agents. Sofantinib 300mg orally, once a day, with continuous administration every 21 days,
until the disease progresses or becomes intolerable; Imaging methods were used every 6 weeks
(±7 days) after enrollment according to RECIST1.1 standard to evaluate the efficacy of tumor.